#Genflow Biosciences Advances Longevity Gene Therapy Trials in Dogs
Genflow Biosciences Plc has announced a significant milestone in its GF-1004 clinical trial aimed at addressing age-related decline in dogs. The trial, which focuses on a novel SIRT6-centenarian gene therapy, has thus far reported no adverse side effects in the treated dogs, marking an important step in confirming the safety profile of this innovative approach.
The ongoing proof-of-concept study, initiated in March 2025, involves a cohort of 28 beagles aged over ten years. Conducted in collaboration with the contract research organization Syngene, the trial administers three distinct types of the SIRT6 gene therapy, designed to target fundamental aging mechanisms shared by both dogs and humans.
The primary goals of the GF-1004 trial include validating the treatment’s safety and efficacy, confirming the feasibility of its administration, and demonstrating various benefits such as:
Reduced biological age as assessed by the GRIM methylation clock
Increased muscle strength and mass
Improved mitochondrial function
Enhanced coat quality
Better overall health metrics
Following the treatment phase, the trial will transition into a five-month follow-up period, expected to conclude in January 2026.
Success in the GF-1004 trial is anticipated to pave the way for potential partnerships with major animal health companies. Genflow aims to leverage compelling preclinical data to negotiate strategic licensing agreements, thereby enhancing market opportunities. Given that dogs and humans share conserved pathways in aging, the positive results from this trial could also facilitate future research into human longevity therapeutics.
Founded in 2020, Genflow Biosciences is positioned as the only publicly listed company in Europe focused on longevity. The firm is dedicated to developing gene therapies that not only extend lifespan but also improve the quality of life in companion animals. Other clinical trials, including studies on GF-1002, are also planned for 2025, exploring treatments for chronic liver diseases.
The GF-1004 study represents a pivotal advancement in gene therapy aimed at addressing age-related decline. Success in this trial could not only confirm the safety and efficacy of GF-1004 in dogs but may also pave the way for similar therapies in humans, tapping into a large and growing market.
GF-1004 is designed to enhance overall health quality in companion animals. Benefits such as increased muscle strength, improved mitochondrial function, and better health metrics reflect its potential for substantial impacts on animal wellbeing, making it an appealing option for pet owners.
GF-1004 targets fundamental biological mechanisms of aging, specifically at the mitochondrial and epigenetic levels. This innovative approach aligns with growing scientific research suggesting that addressing these mechanisms can significantly improve health span in both animals and potentially humans.
The lack of reported adverse effects during the GF-1004 trial is a positive indicator of its safety profile, which is crucial for the next stages of development. Such results build confidence among stakeholders and could enhance the company’s position for future partnerships.
The long-term objective is to develop GF-1004 into a commercially viable product, potentially securing a licensing agreement with an established Animal Health company. This strategy could substantially accelerate market entry and broaden clinical applications.
Success in the canine study could serve as a crucial stepping stone for translating findings to human health applications. As dogs and humans share conserved aging pathways, positive outcomes may open doors to significant advancements in human longevity therapeutics.
As the only publicly listed longevity-focused company in Europe, Genflow is uniquely positioned within a rapidly expanding market. Its pioneering work in gene therapy for aging could attract considerable investor interest as the clinical outcomes from trials start to materialise.
Following the completion of the ongoing trial, Genflow aims to leverage the resultant data for securing partnerships and advancing other therapeutic initiatives. This strategic focus could enhance its growth prospects in both the veterinary and human health markets.